Presented at TIDES USA 2022 by Gerard Platenburg - ProQR Therapeutics.
Published on at TIDES USALink Download
Antisense oligonucleotides (AONs) have been used as therapeutics for the last few decades. ProQR has built an extensive pipeline of investigational RNA therapies based on the technologies already available. We have gone beyond that and are developing an entirely new way of using oligonucleotides for the treatment of genetic diseases based on RNA base editing. These Editing Oligonucleotides (EONs) make specific single nucleotide edits to RNA to reverse mutations.
Gerard is a co-founder and has served as our Chief Scientific Officer since 2022, following his tenure as Chief Innovation Officer from 2014 to 2022. Gerard has an extensive background in RNA modulation and orphan drug discovery and development and is currently in charge of our Innovation unit.
Author(s): Doherty EE, et al.